Computational Models and Target Discovery in ACC

Preclinical and Translational Models

Computational models and target discovery in adrenocortical carcinoma (ACC) refer to bioinformatic, network-based, and machine-learning methods used to identify molecular programs associated with tumor behavior and to prioritize candidate therapeutic targets. Within the ACC research hierarchy, these approaches belong to preclinical and translational investigation rather than routine diagnosis or treatment selection. They are intended to generate testable hypotheses from genomic and transcriptomic data, especially in a rare malignancy where conventional target-discovery pipelines are difficult to scale.¹²

This area has developed in response to several structural constraints in ACC research, including small cohorts, marked biologic heterogeneity, and limited prospective therapeutic development. Integrative analyses of public datasets may reveal recurring pathways despite low sample numbers, but most studies remain retrospective and depend on mixed platforms, incomplete clinical annotation, and limited external validation.³⁴ As a result, computational findings generally provide stronger support for broad biologic themes than for any single ranked gene, pathway, or drug candidate.

Across the available literature, the most reproducible signal is enrichment of proliferation-associated biology, particularly cell-cycle regulation, mitotic control, and genomic-instability-related programs.²³ Additional studies nominate migration-related networks, regulatory axes, and repurposed compounds, but these findings are more model-dependent and less consistently validated.¹⁴ In current ACC care, computational target discovery therefore remains complementary to established management strategies such as surgery, mitotane-based treatment, and conventional systemic therapy selection, rather than a substitute for them.¹

Diagnostic and translational context

ACC target discovery is shaped by the rarity of the disease and the resulting scarcity of large, well-annotated molecular cohorts. Computational methods attempt to address this problem by combining transcriptomic datasets, constructing interaction or coexpression networks, and ranking genes according to recurrence, prognostic association, or predicted druggability.¹³ In principle, this can reduce the search space for downstream laboratory validation.

The most reliable output of these approaches is identification of recurrent biologic programs across datasets. The least reliable output is precise prioritization of individual targets or compounds, because rankings may change with cohort composition, preprocessing choices, and model design.¹⁴ The practical implication is that computational analyses may help focus experimental work, but they do not by themselves establish a validated therapeutic dependency.

From this context, the literature is most coherently organized around recurrent ACC biologic programs, target nomination and drug matching, and the methodological limits that affect interpretation.

Recurrent biologic programs

Cell-cycle and mitotic regulation

The dominant recurring theme in ACC computational studies is dysregulation of cell-cycle progression, G2/M transition, mitotic spindle function, checkpoint signaling, and related p53-associated pathways.³ Hub-gene analyses repeatedly identify proliferative regulators such as CDK1, cyclins, TOP2A, AURKA, and related mitotic machinery, suggesting that aberrant cell division is a central feature of ACC molecular biology rather than an isolated result from one dataset.²³

This is one of the more reproducible conclusions in the field because it recurs across different datasets and analytic strategies. What remains less certain is whether any individual hub gene is a tractable therapeutic vulnerability rather than simply a marker of aggressive growth. Clinically, the implication is mainly translational: cell-cycle biology appears to be a reasonable area for focused preclinical investigation, but computational recurrence alone is not sufficient to justify target-directed treatment claims.²³

Emerging regulatory and invasive phenotypes

Beyond canonical proliferation signatures, some analyses propose additional regulatory axes associated with aggressive behavior, including links between proliferative programs and migration or invasion-related phenotypes.²⁴ These findings support a view of ACC as biologically heterogeneous, with at least some tumors showing overlapping growth and motility programs rather than a single dominant molecular driver.

The reliable conclusion is limited but important: computational studies suggest layered regulatory complexity in ACC. What is not yet reliable is the generalizability of these proposed axes across ACC subgroups or their status as true therapeutic liabilities. In practice, these findings are best interpreted as leads for mechanistic studies rather than as established biomarkers or targets.⁴

Target nomination and computational drug matching

Once recurrent pathways are identified, a related goal is to nominate specific targets for experimental follow-up. Some ACC studies combine public survival-linked datasets with limited functional work in cell models, showing that perturbation of selected genes may affect proliferation, cell-cycle progression, or migratory behavior.²⁴ This moves beyond simple correlation, but it still does not establish in vivo efficacy, adrenal specificity, or clinical utility.

Network-based drug-repositioning studies extend the same logic by connecting disease profiles, candidate targets, and existing compounds to generate ranked therapeutic hypotheses for ACC.¹⁵ This approach is attractive in a rare cancer because repurposing may be more feasible than de novo drug development. However, the outputs are highly sensitive to network structure and available annotations, and they may not capture endocrine context, adrenal-specific pharmacology, resistance biology, or the difference between target association and meaningful treatment response.¹⁵

Taken together, computational target nomination is reasonably useful for prioritizing compounds and pathways for preclinical testing. It is not a reliable predictor of patient benefit when used in isolation. Compared with standard therapeutic decision-making, its value currently lies in research prioritization rather than direct clinical selection.¹

Methodologic limitations and interpretive pitfalls

Interpretation of ACC computational studies is consistently limited by small retrospective cohorts, overlapping public cases, mixed assay platforms, and incomplete data on endocrine phenotype, treatment exposure, and outcome definitions.³⁴ These features increase the risk of overfitting and may produce apparently precise rankings that do not persist in independent validation sets.

More general survival-modeling literature that includes ACC also emphasizes the importance of cross-validation, permutation testing, and careful endpoint definition, while suggesting that restricting analyses to protein-coding transcripts may overlook relevant non-coding signals.⁶ The reliable methodological principle is that internal statistical performance does not guarantee external validity. The practical implication is that replication across datasets and validation in ACC-relevant experimental systems remain essential.

A further limitation is the gap between prognostic association and therapeutic tractability. Genes associated with stage or survival may simply reflect aggressive biology, and even supportive knockdown experiments may demonstrate biologic relevance without proving selective vulnerability or druggability.²⁴ For researchers, computational target discovery is therefore best viewed as one step in a larger validation pipeline.

Indirect evidence from cross-cancer machine-learning and systems-biology studies reinforces this caution. Expression-based classifiers, synthetic-lethality frameworks, and pathway-derived prognostic signatures may perform well in other tumor types or show nominal transferability to ACC, but their relevance to adrenal tumors remains uncertain without ACC-specific training and validation.⁷⁸⁹¹⁰ Similarly, pan-cancer non-coding RNA analyses suggest that models based only on canonical transcript summaries may miss important regulatory complexity.¹¹ These findings are methodologically informative, but they provide only limited direct evidence for ACC-specific target discovery.

Role in research and model development

These limitations define the current role of computational modeling in ACC research. Its principal value is to reduce a large molecular search space to a smaller set of candidate pathways for mechanistic study, biomarker development, and focused drug testing.¹³ The field appears most mature when multiple datasets converge on broad biologic programs and least mature when strong therapeutic recommendations are inferred from ranking algorithms alone.

Related computational work in the H295R adrenocortical cell system illustrates a broader ecosystem of ACC-derived models. Studies of steroidogenesis and endocrine perturbation have used H295R data for structure-based prediction and mechanistic modeling, showing that ACC-derived systems can support computational prioritization beyond tumor target discovery itself.¹²¹³ Although this evidence is indirect for oncology, it underscores the importance of adrenal-specific biologic context when interpreting computational outputs.

Overall, current evidence supports feasibility and biologic plausibility more strongly than clinical utility. Future progress will likely depend on integrating transcriptomic findings with additional molecular layers, endocrine phenotype, and treatment-response data, followed by validation in models that better reflect ACC heterogeneity.²⁴

Included Articles

• PMID 32483162: This article applies a heterogeneous-network computational drug-repositioning method to ACC and generates ranked candidate drug, target, and disease-target associations, including predicted links involving cosyntropin and targets such as IGF1R and TOP2A. It frames these outputs as hypothesis-generating leads to accelerate experimental and clinical evaluation in a rare cancer with limited effective therapies.¹

• PMID 34512018: Using TCGA and other public datasets together with ACC cell-line experiments, this study identified BCLAF1 as a proliferation-associated factor linked to poor prognosis and cell-cycle programs. BCLAF1 knockdown reduced proliferation and altered G2/M progression, with correlated regulation of CDK1 and cyclin B1.²

• PMID 38053725: Integrated bioinformatic analysis of three GEO microarray datasets identified 206 differentially expressed genes in ACC, with enrichment centered on cell-cycle and p53-related pathways. Eight hub genes, including CDK1, CCNA2, CCNB1, TOP2A, MAD2L1, BIRC5, BUB1, and AURKA, were upregulated and associated with tumor stage and worse survival in validation analyses.³

• PMID 41540175: This study used integrated bioinformatics and machine learning across 311 samples, followed by in vitro knockdown and rescue experiments, to identify an APOBEC3B-ANLN regulatory axis in ACC. APOBEC3B suppression reduced ANLN expression and cell migration, while ANLN overexpression restored migratory behavior.⁴

• PMID 31607216: A pan-cancer TCGA survival-analysis framework including ACC highlighted statistical safeguards such as cross-validation and permutation testing, while also discussing immortal time bias in disease-free endpoints. It further suggested that non-coding RNAs may have prognostic performance comparable to protein-coding genes, broadening the transcript classes relevant to ACC computational discovery even though the findings were not ACC-specific.⁶

• PMID 37841081: An EPA-linked computational toxicology study used high-throughput H295R steroidogenesis assay data to build structure-based models that predict which untested chemicals are likely to perturb steroid hormone biosynthesis. Its relevance to ACC is indirect, but it shows how an ACC-derived cell line can support computational prioritization in endocrine and toxicology research beyond tumor-target discovery.¹²

• PMID 21725065: A mechanistic computational model in H295R cells incorporated cell proliferation and oxysterol metabolism to improve prediction of cholesterol and steroid time-course responses to metyrapone. Although developed for endocrine-active chemical screening rather than ACC therapeutics, it adds nuance to the note’s discussion of H295R-based computational applications outside direct target discovery.¹³

• PMID 32257050: An expression-based MSI classifier showed high performance across several non-ACC cancer cohorts and platforms, illustrating the technical potential of compact machine-learning signatures. Its relevance to ACC is indirect and mainly methodological, highlighting both the promise and the limited transferability of cross-cancer models to rare adrenal tumors.⁷

• PMID 32542110: A pan-cancer study of let-7 and miR-10 isomiRs found that non-canonical, seed-shifted isoforms can rewire miRNA:mRNA regulatory networks and alter pathway or drug-response associations relative to canonical miRNAs. Its relevance to ACC is indirect, but it adds a caution that ACC computational models may miss important non-coding regulatory complexity when relying on canonical miRNA-level summaries alone.¹¹

• PMID 33240468: A pan-cancer integrative omics study of candidate synthetic-lethal gene pairs suggests that many nominated genes converge on cell-cycle and p53-related programs, while emphasizing that pair selection is shaped by cross-species prediction, human database curation, and multi-omic filtering rather than tumor-specific validation. For ACC, the relevance is therefore indirect and mainly methodological, reinforcing synthetic lethality as a hypothesis-generation framework rather than a validated source of ACC-specific targets.⁸

• PMID 36292980: An HCC analysis derived a four-gene mitophagy-related prognostic signature that also showed predictive signal in ACC, suggesting possible cross-cancer transferability of pathway-based expression models. In the ACC note, this is best treated as indirect support for classifier feasibility rather than ACC-specific biologic validation.⁹

• PMID 36468004: A gastric-cancer HRD expression signature showed cross-cancer correlation with HRD scores in several TCGA tumor types, including ACC. In the ACC note, this is best treated as indirect support for the feasibility of DNA-repair-related cross-cancer classifiers, while emphasizing the need for adrenal-specific validation before translational use.¹⁰

• PMID 41219379: A publisher correction to a 2025 Scientific Reports ACC study clarified a figure but did not materially change the study’s underlying message: coexpression network analysis nominated HMMR and linked it to fluorouracil and epirubicin as repurposing candidates, with high reported internal ROC performance for several hub genes.⁵

References

Footnotes

1. A computational drug repositioning method applied to rare diseases: Adrenocortical carcinoma.. Sci Rep. 2020. PMID: 32483162. Local full text: 32483162.md ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰

2. Role of Bclaf1 in Promoting Adrenocortical Carcinoma Proliferation: A Study Combining the Use of Bioinformatics and Molecular Events.. Cancer Manag Res. 2021. PMID: 34512018. Local full text: 34512018.md ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹

3. Identification of key genes and pathways in adrenocortical carcinoma: evidence from bioinformatic analysis.. Front Endocrinol (Lausanne). 2023. PMID: 38053725. Local full text: 38053725.md ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹

4. Machine Learning-Driven Identification and In Vitro Validation of the APOBEC3B-ANLN Regulatory Axis in Adrenocortical Carcinoma.. Endocrine. 2026. PMID: 41540175. Local full text: 41540175.md ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰

5. Publisher Correction: Adrenocortical carcinoma survival gene HMMR was identified as being targeted by fluorouracil and epirubicin using a gene coexpression network-based drug repositioning strategy.. Sci Rep. 2025. PMID: 41219379. Local full text: 41219379.md ↩ ↩² ↩³

6. Advancing Pan-cancer Gene Expression Survial Analysis by Inclusion of Non-coding RNA.. RNA Biol. 2020. PMID: 31607216. Local full text: 31607216.md ↩ ↩²

7. PreMSIm: An R package for predicting microsatellite instability from the expression profiling of a gene panel in cancer.. Comput Struct Biotechnol J. 2020. PMID: 32257050. Local full text: 32257050.md ↩ ↩²

8. Integrative omics analysis reveals relationships of genes with synthetic lethal interactions through a pan-cancer analysis.. Comput Struct Biotechnol J. 2020. PMID: 33240468. Local full text: 33240468.md ↩ ↩²

9. A Mitophagy-Related Gene Signature for Subtype Identification and Prognosis Prediction of Hepatocellular Carcinoma.. Int J Mol Sci. 2022. PMID: 36292980. Local full text: 36292980.md ↩ ↩²

10. Potential value of the homologous recombination deficiency signature we developed in the prognosis and drug sensitivity of gastric cancer.. Front Genet. 2022. PMID: 36468004. Local full text: 36468004.md ↩ ↩²

11. Rewired functional regulatory networks among miRNA isoforms (isomiRs) from let-7 and miR-10 gene families in cancer.. Comput Struct Biotechnol J. 2020. PMID: 32542110. Local full text: 32542110.md ↩ ↩²

12. Evaluating structure-based activity in a high-throughput assay for steroid biosynthesis.. Comput Toxicol. 2022. PMID: 37841081. Local full text: 37841081.md ↩ ↩²

13. Mechanistic computational model of steroidogenesis in H295R cells: role of oxysterols and cell proliferation to improve predictability of biochemical response to endocrine active chemical—metyrapone.. Toxicol Sci. 2011. PMID: 21725065. Local full text: 21725065.md ↩ ↩²